Translating Dual-Targeting T-Cell Engager Strategies into Clinical Success Through Biomarker-Driven Development & Early Human Insights
- Exploring how the dual-targeting design of LBL-051 is being leveraged to enhance therapeutic selectivity, deepen immune-cell depletion, and improve safety profiles, while addressing key translational challenges
- Evaluating predictive biomarkers, pharmacodynamic readouts, and translational immune-monitoring strategies that can validate target engagement, characterize immune-cell depletion, and support earlier assessment of clinical activity and durability
- Connecting emerging lessons from the evolving autoimmune T-cell engager clinical landscape with the development of LBL-051, using early human data and translational science to inform dose optimization, patient selection, and future clinical development strategies